Generics BulletinA decade after Teva’s largest-ever deal, the $40.5bn purchase of Allergan’s Actavis Generics unit, the shadow of that transaction continues to loom over the Israeli group. “In the past, after the Acta
Generics BulletinAccord Healthcare, Sandoz and Teva have failed to convince the Court of Appeal of England and Wales to overturn a lower court order that the UK part of a key patent shielding Astellas’ $6.2bn Xtandi (
Generics BulletinA dedicated program to boost complex generics, more transparency into the abbreviated new drug application review process, and clearer opportunities for communication with US Food and Drug Administrat
Pink SheetA dedicated program to boost complex generics, more transparency into the abbreviated new drug application review process, and clearer opportunities for communication with US Food and Drug Administrat